Sales rise 32.79% to Rs 229.20 crore
Net profit of Sanofi Consumer Healthcare India rose 35.60% to Rs 67.80 crore in the quarter ended March 2026 as against Rs 50.00 crore during the previous quarter ended March 2025. Sales rose 32.79% to Rs 229.20 crore in the quarter ended March 2026 as against Rs 172.60 crore during the previous quarter ended March 2025.
Sanofi Consumer Healthcare India standalone net profit rises 35.60% in the March 2026 quarter
April 29, 2026 · 9:04 am IST
Source: Business Standard
📌
Key Takeaways
- Sales rise 32.79% to Rs 229.20 crore Net profit of Sanofi Consumer Healthcare India rose 35.60% to Rs 67.80 crore in the quarter ended March 2026 as against Rs 50.00 crore during the previous quarter ended March 2025.
- Sales rose 32.79% to Rs 229.20 crore in the quarter ended March 2026 as against Rs 172.60 crore during the previous quarter ended March 2025.
📊
IPO Market Today
Open for Subscription 1
Amba Auto Sales
SME
₹130–₹135
· Closes Apr 29
GMP: —
Sub: 0.66x
Full Report
Originally reported by Business Standard.
💡
IPO Cracker Take
This market development has implications for IPO investors tracking upcoming issues. See our IPO calendar and live GMP data for the most recent moves.
❓
Frequently Asked Questions
Market news feeds into IPO pricing decisions, subscription timing, and listing-day sentiment. Track the broader market daily alongside each active IPO's own fundamentals.
Our IPO calendar shows all upcoming, open, and recently listed issues in one place — with price band, GMP, and subscription data.
We publish daily market and IPO news, live GMP updates, and subscription tracking. Bookmark our News page or follow us on social media for real-time updates.
Explore More
Quick links to all IPO sections
Open IPO
Live now
Upcoming IPO
Coming soon
IPO Calendar
Dates & schedule
Closed IPO
Allotment pending
Listed IPO
Listing gains
IPO GMP
Grey market premium
Subscription
Live bidding data
Allotment
Check status
SME IPO
Small & medium
Mainboard IPO
Large cap
Performance
Listing returns
Market News
Latest updates
Learn
IPO guides
0 Comments
No comments yet. Be the first to share your opinion!